fda approved uses for glp 1 Advancements in approvals pediatric obesity treatment GLP-1 Medications for Weight Loss:

One dose-response meta-analysis of randomized trials found berberine reduced: BMI by about 0.29 kg/m Waist circumference by about 2.75 cm Body weight : no significant change in that analysis That can be meaningful for cardiometabolic risk over time, but it is not melt fat fast. Also, NCCIH emphasizes that there have not been many well-controlled human trials for weight loss, so confidence is limited

Combination of berberine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats

GLP-1R expression levels exhibit an inverse association with the Gleason score in prostate cancer (146)

Neither acute nor chronic exposure to GIP or GIPRAs affects gastric emptying in healthy individuals or those with T2DM (151)

Consider semaglutide: an -aminoisobutyric acid (Aib) at position 8 locks the peptide against degradation by the DPP-4 enzyme, while a C18 fatty acid chain attached at lysine 26 enables a convenient once-weekly dosing schedule

It really hasnt been an option thats been provided before for prescription drugs